Table 3

Univariable and multivariable analysis for progression-free survival.

Variables (N=50)	N	Univariate analysis		Multivariable analysis

		Median PFS, mo (95% CI)	P	Hazard ratio (95% CI)	P
Patient age (yr)			0.837		-
<66	19	23.9 (15.4–51.3)		-
≥66	31	18.9 (12.6–29)		-
Sex			0.496		-
Male	27	23.9 (15.4–31.4)		-
Female	23	18.9 (12.6–24.9)		-
Type of myeloma			0.605		-
IgG	25	24.2 (15.4–49.3)		-
Non-IgG	25	18.9 (12.6–24.9)		-
Type of light chain			0.649		-
Kappa	33	18.9 (15.4–25.5)		-
Lambda	17	24.6 (8.5–51.3)		-
Lactate dehydrogenase			0.373		-
>Upper limit of normal	31	23.9 (16.3–31.4)		-
Normal	19	22.2 (8.5–26)		-
ISS stage at diagnosis			0.826		-
I or II	22	24.2 (18.2–31.4)		-
III	26	16.5 (8.8–51.3)		-
Unknown	2			-
Cytogenetic status			0.536		-
Standard risk	26	23.9 (16.3–31.2)		-
High risk	13	23.5 (8.5–51.3)		-
Unknown	11			-
Extramedullary disease			0.925		-
Present	8	25.1 (6–52.8)		-
None	42	22.2 (14.8-25.6)		-
Transplant eligibility			0.601		-
No	36	18.9 (12.6–24.9)		-
Yes	14	26.5 (15.4–51.3)		-
BRAF V600E mutation			0.04		0.623
No	43	23.9 (16.5–31.2)		1
Yes	7	18.2 (1.8–24.2)		1.32 (0.44–3.98)
RAS/RAF mutation			0.015		0.018
No	36	24.0 (16.5–49.3)		1
Yes	14	18.2 (3.6–24.2)		2.28 (1.15–4.5)

Abbreviations: CI, confidence interval; PFS, progression free survival; RAS/RAF, any of KRAS, NRAS and/or BRAF mutations.